Ery-Ped (ERYTHROMYCIN ETHYLSUCCINATE)
Ery-Ped (ERYTHROMYCIN ETHYLSUCCINATE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Ery-Ped; Generic name: ERYTHROMYCIN ETHYLSUCCINATE; Manufacturer: Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals).
| Brand name | Ery-Ped |
|---|---|
| Generic name | ERYTHROMYCIN ETHYLSUCCINATE |
| Manufacturer | Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals) |
| Used for | INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, Ery-Ped should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ery-Ped is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respirato |
| Dosage | DOSAGE AND ADMINISTRATION Ery-Ped (erythromycin ethylsuccinate) oral suspensions may be administered without regard to meals. Children Age, weight, and severity of the infection are important factors in determining the proper dosage. In mild to moderate infections, the usual dosage of erythromycin ethylsuccinate for children is 30 to 50 mg/kg/day in equally divided doses every 6 hours. For more severe infections this dosage may be doubled. If twice-a-day dosage is desired, one-half of the total |
| Warnings | WARNINGS Hepatotoxicity There have been reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, occurring in patients receiving oral erythromycin products. QT Prolongation Erythromycin has been associated with prolongation of the QT interval and infrequent cases of arrhythmia. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving erythromycin. Fata |
| Active ingredient(s) | ERYTHROMYCIN ETHYLSUCCINATE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04775721-ab87-4b66-808c-d67a21032385 |